A new post-approval study of over 1.6 million Danish women has shown that the quadrivalent human papillomavirus (HPV) vaccine poses no increased risk of blood clots at any time within 42 days of receiving the immunization. The report appears in the July 9th issue of JAMA, the Journal of the American Medical Association.
Hey, check out all the research scientist jobs. Post your resume today!
